Skip to content

Prognostic Value of Plasma Biomarkers Among Patients With Hypertension

Prognostic Value of Plasma Biomarkers Among Patients With Hypertension

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04107584
Acronym
BIOMS-HTN
Enrollment
600
Registered
2019-09-27
Start date
2017-04-01
Completion date
2022-08-31
Last updated
2019-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

Hypertension is the most important risk factor for cardiovascular and cerebrovascular diseases,and also a substantial public health problem. The purpose of the study is to investigate the association between plasma biomarkers and adverse outcomes in patients with hypertension.

Interventions

None listed

Sponsors

Beijing Institute of Heart, Lung and Blood Vessel Diseases
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* \>18 years old * In accordance with the diagnosis of hypertension (BP≥140/90mmHg)

Exclusion criteria

* The

Design outcomes

Primary

MeasureTime frameDescription
Primary mortality of hypertensionThrough study completion, an average of 2 yearsThe incidence rate of primary mortality of hypertension

Secondary

MeasureTime frameDescription
Secondary outcomes of heartThrough study completion, an average of 2 yearsThe incidence rate of left ventricular hypertrophy, myocardial infarction, congestive heart failure, and arrhythmia
Secondary outcomes of brainThrough study completion, an average of 2 yearsThe incidence rate of stroke (include cerebral hemorrhage and cerebral ischemia
Secondary outcomes of kidneyThrough study completion, an average of 2 yearsThe incidence rate of hypertensive renal injure and end-stage renal disease
Secondary outcomes of eyesThrough study completion, an average of 2 yearsThe incidence rate of hypertensive eye injure

Countries

China

Contacts

Primary ContactYulin Li, PhD
lyllyl_1111@163.com0086-010-64456453

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026